Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Tue, 10.05.2022
Formycon AG
Press Release // May 10, 2022
Formycon AG and ATHOS KG announce closing of transaction to acquire biosimilar assets FYB201 and FYB202 as well as Bioeq GmbH
- Full acquisition of biosimilar candidate FYB202 (ustekinumab) and acquisition of a 50% stake in biosimilar candidate FYB201 (ranibizumab) completed
- Takeover of the operational developm [ … ]
Thu, 14.04.2022
Formycon AG
First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN:
DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 78,00 auf EUR 89,00.
Zusammenfassung:
Formycon hat eine €650 Mio.-Transaktion mit dem Unternehmen Athos KG der
Gebrüder Strüngm [ … ]
Tue, 29.03.2022
Formycon AG
Press Release // March 29, 2022
Formycon is acquiring the biosimilar assets FYB201 and FYB202 and strengthening its position in the global growth market of biosimilars through long-term partnership with ATHOS KG
- Total value of transaction volume approximately Euro 650 million
- Complete acquisition of biosimilar candidate FYB202 (ustekinumab) [ … ]
Tue, 29.03.2022
Formycon AG
Publication of insider information in accordance to Article 17 of Regulation (EU) No. 596/2014Ad Hoc Announcement // March 29, 2022
Formycon and ATHOS KG merge development activities through the acquisition of biosimilar assets in a long-term strategic partnership
Munich - Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) ("Formycon") and ATHOS KG ( [ … ]
Tue, 14.12.2021
Formycon AG
Press Release // December 14, 2021
MS Pharma becomes Partner for the Commercialization of FYB201, Formycon's Biosimilar Candidate to Lucentis(R)1 (ranibizumab), in the MENA Region
Munich - Bioeq AG ("Bioeq"), licensee and exclusive holder of the worldwide commercialization rights for FYB201, Formycon's biosimilar candidate for Lucentis(R) (ranibi [ … ]
Thu, 09.12.2021
Formycon AG
Press Release // December 9, 2021
Formycon and Scientists from TUM publish new Data on broadly effective SARS-CoV-2 antiviral Drug FYB207
- Joint study describes optimized ACE2-IgG4-Fc fusion proteins
- Picomolar Neutralization of the SARS-CoV-2 variants of concern
- Neutralizing effect of SARS-CoV-2 delta variant confirmed
- High efficacy [ … ]
Tue, 09.11.2021
Formycon AG
Press Release // November 9, 2021
Formycon Reports its Nine-Month Figures for 2021
- Strong topline growth to Euro 29.1 million compared to previous year
- Forecast for full-year revenues concretized and raised to around Euro 40 million
- EBITDA of Euro -10.0 million and net result for the period of Euro -10.7 million in line with plans
- [ … ]
Tue, 19.10.2021
Formycon AG
Press Release // October 19, 2021
Formycon and SCG Cell Therapy Announce Collaboration and License Agreement for Formycon's COVID-19 Drug FYB207
- Agreement aims to accelerate development and commercialization of FYB207 in the Asia-Pacific region
- SCG Cell Therapy receives exclusive license to develop, manufacture and commercialize FYB207 i [ … ]
Mon, 18.10.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // October 18, 2021
Formycon Concludes Collaboration and License Agreement with SCG Cell Therapy for its COVID-19 Drug FYB207 for the Asia Pacific Region
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and SCG Cell Therap [ … ]
Fri, 01.10.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // October 1, 2021
Formycon and Bioeq announce File Acceptance for FYB201, a biosimilar candidate to Lucentis(R) (ranibizumab) by the U.S. Food and Drug Administration (FDA)
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) [ … ]